<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04533880</url>
  </required_header>
  <id_info>
    <org_study_id>20-00081</org_study_id>
    <nct_id>NCT04533880</nct_id>
  </id_info>
  <brief_title>The Effect of Bone-void Filler on Anterior Knee Pain Following ACL Reconstruction</brief_title>
  <official_title>The Effect of Bone-void Filler on Anterior Knee Pain Following ACL Reconstruction With Bone-Patellar Tendon Bone Autograft</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of the common complaints after ACLR with BPTB autograft anterior knee pain. It is thought&#xD;
      that this may be due to harvesting the patellar tendon for graft use. Specifically, this may&#xD;
      be due to the bone defect that is left after graft harvesting. There is currently no&#xD;
      consensus on a gold standard for treating the bone defect with surgeons using multiple&#xD;
      commercially available bone void fillers as well as autologous bone graft in standard&#xD;
      practice.&#xD;
&#xD;
      The purpose of the proposed study is to evaluate the effect bone-void filler on anterior knee&#xD;
      pain following ACL reconstruction BPTB autograft.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score on Knee injury and Osteoarthritis Outcome Score (KOOS) Survey</measure>
    <time_frame>Month 12 Post-Op</time_frame>
    <description>The KOOS survery is comprised of 42 questions. The questions are divided into 5 sub-categories: symptoms (7 questions), pain (9 questions), function/daily living (17 questions), function/sports and recreational activities (5 questions), quality of life (4 questions). The total range for each sub-category is 0-100, making the total range for the whole survey 0-500. The higher the score, the worse the symptoms and pain / higher difficulty in function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Score on Kujala Anterior Knee Pain Scale (AKPS)</measure>
    <time_frame>Month 12 Post-Op</time_frame>
    <description>The Kujala AKPS is a 13-item screening instrument designed to assess patellofemoral pain in adolescents and young adults, with a variable ordinal response format. For example, a 'Limp' score would be scored as follows: none (5), slight/periodic (3), constant (0). Total scores range from 0 to 100. The lower the score, the better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Score on International Knee Documentation Committee (IKDC Questionnaire)</measure>
    <time_frame>Month 12 Post-Op</time_frame>
    <description>The IKDC contains 2 quantitatively measurable questions. Each question is scored 0-10, for a total range of 0-20. The higher the score, the more pain was experienced.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VAS Score for Anterior Knee Pain</measure>
    <time_frame>Month 12 Post-Op</time_frame>
    <description>The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain.&quot; The total score range is 0-10; the higher the score, the worse the pain.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>ACL</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will receive autologous bone obtained from the BTBPB graft harvest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous Bone + DBM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Autologous bone plus demineralized bone matrix</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous Bone + Calcium Phosphate Cement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Autologous bone plus calcium phosphate cement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DBM</intervention_name>
    <description>Demineralized bone matrix (Allosync, CDMB Putty, Arthrex, Naples, FL)</description>
    <arm_group_label>Autologous Bone + DBM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Calcium phosphate cement</intervention_name>
    <description>Quickset, Arthrex, Naples, FL</description>
    <arm_group_label>Autologous Bone + Calcium Phosphate Cement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous bone graft</intervention_name>
    <description>Autologous bone grafting involves utilizing bone obtained from the same individual receiving the graft</description>
    <arm_group_label>Autologous Bone + Calcium Phosphate Cement</arm_group_label>
    <arm_group_label>Autologous Bone + DBM</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing ACLR with BPTB autograft&#xD;
&#xD;
          -  Skeletally mature (as defined by closed growth plates on plain radiograph)&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Willing and able to provide consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  knee with intact ACL&#xD;
&#xD;
          -  skeletally immature (as defined by open physis on plain radiograph)&#xD;
&#xD;
          -  pregnant&#xD;
&#xD;
          -  less than 18 years of age&#xD;
&#xD;
          -  previous ACL repair or reconstruction&#xD;
&#xD;
          -  unable to speak english or perform informed consent&#xD;
&#xD;
          -  multiligamentous knee injury (two or more ligaments requiring surgical attention)&#xD;
&#xD;
          -  varus or valgus malalignment greater than 3 degrees&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Strauss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Strauss, MD</last_name>
    <phone>646-501-7223</phone>
    <email>eric.strauss@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eoghan Hurley, MB, BCh, MCh</last_name>
    <phone>646-501-7223</phone>
    <email>eoghan.hurley@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NYU Langone Orthopedic Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Strauss, MD</last_name>
      <phone>646-501-7223</phone>
      <email>eric.strauss@nyulangone.org</email>
    </contact>
    <contact_backup>
      <last_name>Eoghan Hurley, MB, BCh, MCh</last_name>
      <phone>6465017223</phone>
      <email>eoghan.hurley@nyulangone.org</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Strauss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be provided upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to eric.strauss@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

